In this study, the effect of AZD1775 as a single agent or in combination with olaparib or gemcitabine was investigated in gynecological cancer cells with the hypothesis that this strategy would be particularly effective against cells with mutated p53. Here, TP53 is linked to female reproductive organ cancer.